

1. Brown, G., Belkoff, L., Hafron, J. M., Saltzstein, D. R., Potdar, R., Bhaumik, A., Phillips, J., McGowan, T., & Shore, N. D. (2023). Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases. *Targeted oncology*, 18(1), 95–103.
<https://doi.org/10.1007/s11523-022-00932-8>
2. Zurth, C., Koskinen, M., Fricke, R., Prien, O., Korjamo, T., Graudenz, K., Denner, K., Bairlein, M., von Bühler, C. J., Wilkinson, G., & Gieschen, H. (2019). Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. *European journal of drug metabolism and pharmacokinetics*, 44(6), 747–759.
<https://doi.org/10.1007/s13318-019-00577-5>
3. Watanabe, A., Momo, K., Tanaka, K., Kida, M., Kuchira, R., Koshizuka, H., Nishimura, K., Morita, M., Yamamoto, M., & Sasaki, T. (2022). Drug-drug interaction between apalutamide and atorvastatin through breast cancer resistance protein in an outpatient. *International journal of clinical pharmacology and therapeutics*, 60(8), 367–369. <https://doi.org/10.5414/CP204198>
4. Duran, I., Carles, J., Bulat, I., Hellemans, P., Mitselos, A., Ward, P., Jiao, J., Armas, D., & Chien, C. (2020). Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. *Clinical pharmacokinetics*, 59(9), 1135–1148.
<https://doi.org/10.1007/s40262-020-00882-2>
5. Lee, E. H., Gogolin, N. E., & Charpentier, M. M. (2025). Rhabdomyolysis induced by darolutamide and rosuvastatin. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*, 10781552251356456. Advance online publication.
<https://doi.org/10.1177/10781552251356456>
6. Cachafeiro Pin, A. I., Grandío Leivas, L., Caramés Masana, F., Folgar Torres, A., & Naranjo Sánchez, M. A. (2025). Colchicine-enzalutamide interaction: clinical implications and multi-disciplinary management. *European journal of hospital pharmacy : science and practice*, ejhpharm-2024-004459. Advance online publication. <https://doi-org.qe2a-proxy.mun.ca/10.1136/ejhpharm-2024-004459>
7. Leblanc, K., Edwards, S. J., Dranitsaris, G., Leong, D. P., Carrier, M., Malone, S., Rendon, R. A., Bond, A. M., Sitland, T. D., Zalewski, P., Wang, M., & Emmenegger, U. (2024). Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus. *Cancers*, 16(19), 3336. <https://doi-org.qe2a-proxy.mun.ca/10.3390/cancers16193336>
8. De La Cerda, J., Belkoff, L., Courtney, K. D., Diamond, E., D'Olimpio, J., Dunshee, C., Gervasi, L., Goodman, M., Mittal, K., Morris, D., Sieber, P., Tutrone, R., Ryan, M., Zhong, Y., Ufer, M., & Shore, N. (2025). Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with

Advanced Prostate Cancer: Data from a 52-Week Clinical Trial. *Targeted oncology*, 20(3), 503–517.

<https://doi-org.qe2a-proxy.mun.ca/10.1007/s11523-025-01139-3>

9. Hamman, M. A., Bruce, M. A., Haehner-Daniels, B. D., & Hall, S. D. (2001). The effect of rifampin administration on the disposition of fexofenadine. *Clinical pharmacology and therapeutics*, 69(3), 114–121.
<https://doi-org.qe2a-proxy.mun.ca/10.1067/mcp.2001.113697>
10. Brown, G., Belkoff, L., Hafron, J., Aggarwal, P., Potdar, R., Bhaumik, A., Phillips, J., McGowan, T., Shore, N. (2023). Maintenance of castration with concomitant relugolix and apalutamide (Apa) in patients with high-risk localized prostate cancer (HR-LPC): 1 year update. *Journal of Clinical Oncology*, 41(16).
https://doi.org/10.1200/JCO.2023.41.16_suppl.e17094
11. J&J Medical Connect (2025). ERLEADA Medical Information - Use of ERLEADA in Patients Taking Oral Anticoagulants.
<https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-in-patients-taking-oral-anticoagulants#references-content>
12. Woosley, R. L., Heise, C.W., Gallo, T., Woosley, R.D., Lambson, J., Romero, K. A. (2025). QTdrugs List. *CredibleMeds*. <https://www.crediblemeds.org>
13. Merative Micromedex (2025). Drug database. *IBM Micromedex (College of DuPage Library ed.)*. <http://www.micromedexsolutions.com/>
14. Wolters Kluwer (2025). Lexi-database. *UpToDate Lexidrug*.
<https://store.wolterskluwer CDI.com/CDI>
15. Athenahealth (2019). Epocrates medical references. *Epocrates*.
<https://www.epocrates.com>
16. Product Monograph (PM), Product Information (PI), Summary of Product Characteristics (SmPC) for each of the drugs listed